Early modification of initial HAART regimen associated with poor clinical outcome in HIV patients

AIDS Research and Human Retroviruses

Volumn 23, Issue 6, 2007, Pages 794-800

  Wan, Beom Park ^a   Pyoeng, Gyun Choe ^a   Kim, Sung Han ^a   Jae, Hyun Jo ^a   Ji, Hwan Bang ^a   Hong, Bin Kim ^a   Nam, Joong Kim ^a   Oh, Myoung Don ^a   Kang, Won Choe ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CYTOPENIA; DEATH; DIARRHEA; DRUG HYPERSENSITIVITY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; LIVER FUNCTION TEST; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RASH; RISK FACTOR; SIDE EFFECT; SURVIVAL; TASTE; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; UNIVERSITY HOSPITAL; URETER STONE; VOMITING;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; KOREA; MALE; PROPORTIONAL HAZARDS MODELS;

EID: 34447274039     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.0255     Document Type: Article

References (25)

1. d'Arminio MA, Sabin CA, Phillips A, et al.: The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med 2005;165:416-423.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
3. Hogg RS, Heath KV, Yip B, et al.: Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998;279:450-454.
4. Bini T, Testa L, Chiesa E, et al.: Outcome of a second-line protease inhibitor-containing regimen in patients failing or intolerant of a first highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000;24:115-122.
5. Mocroft A, Phillips AN, Miller V, et al.: The use of and response to second-line protease inhibitor regimens: Results from the EuroSIDA study. AIDS 2001;15:201-209.
6. Deeks SG, Hecht FM, Swanson M, et al.: HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy. AIDS 1999;13: F35-F43.
7. Del RC: Current concepts in antiretroviral therapy failure. Top HIV Med 2006;14:102-106.
8. Chen RY, Westfall AO, Mugavero MJ, et al.: Duration of highly active antiretroviral therapy regimens. Clin Infect Dis 2003;37: 714-722.
9. Wit FW, Van LR, Weverling GJ, et al.: Outcome and predictors of failure of highly active antiretroviral therapy: One-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. J Infect Dis 1999;179:790-798.
10. Park-Wyllie LY, Scalera A, Tseng A, and Rourke S: High rate of discontinuations of highly active antiretroviral therapy as a result of antiretroviral intolerance in clinical practice: Missed opportunities for adherence support? AIDS 2002;16:1084-1086.
11. Duran S, Spire B, Raffi F, et al.: Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials 2001;2:38-45.
12. Miller LG, Golin CE, Hays RD, et al.: Impact of antiretroviral regimen switches on adherence. HIV Clin Trials 2002;3:355-360.
13. Butcher D, Greene J, Duong P, and Markson L: Virologic response associated with a change in protease inhibitor therapy. Arch Intern Med 2000;160:394-395.
14. d'Arminio MA, Lepri AC, Rezza G, et al.: Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS 2000;14:499-507.
15. Yuan Y, L'italien G, Mukherjee J, and Iloeje UH: Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Med 2006;7: 156-162.
16. van Roon EN, Verzijl JM, Juttmann JR, et al.: Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants. J Acquir Immune Defic Syndr Hum Retroviral 1999;20:290-294.
17. O'Brien ME, Clark RA, Besch CL, Myers L, and Kissinger P: Palterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003:34:407-414.
18. Sabundayo BP, McArthur JH, Langan SJ, Gallant JE, and Margolick JB: High frequency of highly active antiretroviral therapy modifications in patients with acute or early human immunodeficiency virus infection. Pharmacotherapy 2006;26:674-681.
19. Mocroft A, Youle M, Moore A, et al.: Reasons for modification and discontinuation of antiretrovirals: Results from a single treatment centre. AIDS 2001;15:185-194.
20. Centers for Disease Control and Prevention: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41:1-19.
21. Manfredi R and Chiodo F: Switch of protease inhibitor-containing HAART in routine clinical practice: A four-year prospective observational study. Int J STD AIDS 2001;12:84-88.
22. d'Arminio MA, Testa L, Adorni F, et al.: Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. AIDS 1998;12:1631-1637.
23. Staszewski S, Morales-Ramirez J, Tashima KT, et al.: Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999;341: 1865-1873.
24. Pantaleo G, Graziosi C, Demarest JF, et al.: Role of lymphoid organs in the pathogenesis of human immunodeficiency virus (HIV) infection. Immunol Rev 1994;140:105-130.
25. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at http://www.AIDSinfo.nih.gov. Accessed January 2, 2007.